Nachrichten zu Aptose Biosciences

Startseite > Aktien > Aptose Biosciences > Nachrichten

Aptose Biosciences Aktie

Aktie

ISIN: CA03835T3091 WKN: A3EENM SYM: APTO Land Flagge CA

Kanada

Zur Watchlist hinzufügen Zum Portfolio hinzufügen

Zum Portfolio hinzufügen

0,4049

USD

+5,83 %

+0,0223 USD

Letzter Kurs 02:00:00 Nasdaq

Geldkurs

17.09.24

0,4000

USD

600 STK

Briefkurs

17.09.24

0,4092

USD

800 STK

Aptose Biosciences Aktie kaufen

Kauf

Verkauf

Neueste Nachrichten

Aptose Announces Results from Special Meeting of Shareholders 05.09.24 · globenewswire · Aptose Biosciences
Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib 30.08.24 · globenewswire · Aptose Biosciences
Aptose Announces Adjournment of its Special Meeting of Shareholders 15.08.24 · globenewswire · Aptose Biosciences
Aptose Reports Results for the Second Quarter 2024 08.08.24 · globenewswire · Aptose Biosciences
Aptose Announces Receipt of Deficiency Notice from Nasdaq 19.07.24 · globenewswire · Aptose Biosciences
Aptose Announces Results from Annual and Special Meeting of Shareholders 18.06.24 · globenewswire · Aptose Biosciences
Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress 14.06.24 · globenewswire · Aptose Biosciences
Aptose Announces Closing of $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules 03.06.24 · globenewswire · Aptose Biosciences
Aptose Announces $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules 31.05.24 · globenewswire · Aptose Biosciences
Aptose Reports Results for the First Quarter 2024 14.05.24 · globenewswire · Aptose Biosciences
Aptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024 06.05.24 · globenewswire · Aptose Biosciences
Aptose Reports Results for the Fourth Quarter and Full Year 2023 26.03.24 · globenewswire · Aptose Biosciences

1
2

Aptose Announces Results from Special Meeting of Shareholders 440 Leser
Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future ... 268 Leser

Aptose Announces Adjournment of its Special Meeting of Shareholders 620 Leser
Aptose Announces Results from Special Meeting of Shareholders 440 Leser
Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future ... 268 Leser
Aptose Reports Results for the Fourth Quarter and Full Year 2023 256 Leser
Aptose Reports Results for the Second Quarter 2024 236 Leser
Aptose Clinical and Preclinical Data to be Presented at European School of Haematology (ESH) 6th ... 192 Leser
Aptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private ... 176 Leser
Aptose to Present at the Cantor Global Healthcare Conference 168 Leser
Aptose to Hold Clinical Update and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th 164 Leser
Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private ... 152 Leser